Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing

Six presentations highlight innovations designed to shorten TIL manufacturing, new nonclinical data on LYL119, new technologies and clinical trials in progress

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, is presenting new nonclinical data at the 38^th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on innovations designed to shorten tumor infiltrating lymphocyte (TIL) manufacturing, LYL119, its second generation ROR1-targeted CAR T cell product candidate, as well as data on new technologies and the design of its two clinical trials in progress.

“We remain confident that generating T cells with the ability to resist exhaustion and qualities of durable stemness will unlock the potential of effective cell therapy for solid tumors, and our SITC presentations highlight the progress we are making across our robust pipeline of product candidates and platform technologies designed to achieve this,” said Gary Lee, Ph.D., chief scientific officer at Lyell. “We also highlight new data on our Epi-R P2 manufacturing process, a manufacturing innovation designed to enable faster delivery of TIL product to patients without sacrificing the desired yield, stemness phenotype and retention of tumor reactive clones.”

Details on the presentations are below.

New Nonclinical Data on LYL119, Innovation in Manufacturing and New Technologies

Four presentations highlight new nonclinical data from Lyell’s product pipeline and research programs, including:

• Lyell’s novel Epi-R P2 manufacturing protocol to shorten delivery time of TIL product to patients
• New nonclinical data on LYL119, Lyell’s second-generation ROR1-targeted CAR T-cell therapy
• A new technology being advanced through a collaboration between Lyell and Outpace to enable tumor-restricted IL-12 activity to enhance solid tumor T cell therapies
• Lyell’s rejuvenation technology which has shown the potential to “turn back” the epigenetic clock to generate more stem-like T cells with reduced epigenetic age and enhanced proliferation ability

A presentation titled “Epi-R P2 protocol produces a scalable polyclonal TIL product with a greater expansion success rate across hot and cold tumors in shorter culture time” highlights Lyell’s Epi-R P2 manufacturing protocol that shortens manufacturing time for TIL while maintaining the desired yield, stemness phenotype and retention of tumor reactive clones. Current TIL production time is approximately four to six weeks. Literature suggests that a shorter culture time is associated with improved cell quality, functionality and positive clinical outcomes in metastatic melanoma patients. Lyell’s Epi-R manufacturing protocols are designed to generate populations of TIL with stem-like properties to potentially improve antitumor activity. Epi-R P2 is an improved TIL manufacturing process that reduces the TIL culture duration to less than three weeks without impacting the quality of TIL.